These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25471126)

  • 1. Establishing a Quality Control System for Stem Cell-Based Medicinal Products in China.
    Yuan BZ
    Tissue Eng Part A; 2015 Dec; 21(23-24):2783-90. PubMed ID: 25471126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The regulatory sciences for stem cell-based medicinal products.
    Yuan BZ; Wang J
    Front Med; 2014 Jun; 8(2):190-200. PubMed ID: 24733351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal Stem Cells as Therapeutics Agents: Quality and Environmental Regulatory Aspects.
    Galvez-Martin P; Sabata R; Verges J; Zugaza JL; Ruiz A; Clares B
    Stem Cells Int; 2016; 2016():9783408. PubMed ID: 27999600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The challenges of regulating stem cell-based products.
    von Tigerstrom BJ
    Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCMO L01-Setting Specifications for Biological Investigational Medicinal Products.
    Krause SO
    PDA J Pharm Sci Technol; 2015; 69(5):569-89. PubMed ID: 26429107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
    Kellathur SN
    Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The control of biological medicinal products produced by recombinant DNA technology.
    Griffiths E
    Dev Biol Stand; 1985; 59():155-9. PubMed ID: 4007273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Premarket Regulation of Tissue Engineered Medical Products in China.
    Wang C; Wang A; Feng X; Ke L; Huang Y; Han Q; Sun X; Yang Z
    Tissue Eng Part A; 2015 Dec; 21(23-24):2806-11. PubMed ID: 26529310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturing of biodrugs: need for harmonization in regulatory standards.
    Sahoo N; Choudhury K; Manchikanti P
    BioDrugs; 2009; 23(4):217-29. PubMed ID: 19697964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline on safety evaluation of cell-based medicinal products for animal use.
    Ku HO; Yi H; Park YI; Jeon BS; Kang HG; Kim YS; Park BK
    J Vet Sci; 2019 Mar; 20(2):e14. PubMed ID: 30944536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics.
    Ishii-Watabe A; Hirose A; Katori N; Hashii N; Arai S; Awatsu H; Eiza A; Hara Y; Hattori H; Inoue T; Isono T; Iwakura M; Kajihara D; Kasahara N; Matsuda H; Murakami S; Nakagawa T; Okumura T; Omasa T; Takuma S; Terashima I; Tsukahara M; Tsutsui M; Yano T; Kawasaki N
    AAPS PharmSciTech; 2015 Oct; 16(5):993-1001. PubMed ID: 26288941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present systems and future needs for risk assessments of biologicals: the perspective of the regulator in the People's Republic of China.
    Xia Y; Zhang Z; Li M
    Rev Sci Tech; 1995 Dec; 14(4):1185-91. PubMed ID: 8639955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.